Literature DB >> 799762

Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms.

.   

Abstract

A review of the clinical features of spontaneous regression of malignant melanoma was undertaken. Thirty-three patients with total regression of primary melanoma ("primary regressors") and 40 (13 of whom were somewhat doubtful) with regression of metastatic disease were reviewed in detail. These patients appeared to represent a typical age incidence of melanoma but the primary regressors showed an unexpected predominance of male over female patients. A variety of unique clinical features of the histories of the patients were noted, but none appeared to explain the regression with any degree of predictability. Cutaneous metastases constituted the most common site of regression, followed, in order, by lymphatic, pulmonary, and hepatic metastases. About 40% of patients with spontaneous regressions appeared to have "spontaneous cure," which implies that the disease had not relapsed either during a long period of follow-up or until death from some other cause. Mechanisms that possibly relate to spontaneous regression of melanoma fall into the following general categories: immunologic, endocrine, pigment metabolic, intracellular, nutritional, and carcinogenic. Further quantitative studies of patients acutally undergoing spontaneous regression or the development of a model of spontaneous regression may be a key to our understanding of this interesting "experiment of nature."

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 799762

Source DB:  PubMed          Journal:  Natl Cancer Inst Monogr        ISSN: 0083-1921


  23 in total

1.  Spontaneous regression of metastatic visceral malignant melanoma.

Authors:  K R Haight; D V Shapira; G W Cates
Journal:  Can Fam Physician       Date:  1984-06       Impact factor: 3.275

Review 2.  Advances in the treatment of metastatic melanoma: adoptive T-cell therapy.

Authors:  Chantale Bernatchez; Laszlo G Radvanyi; Patrick Hwu
Journal:  Semin Oncol       Date:  2012-04       Impact factor: 4.929

3.  In vivo selective expansion of a tumour-specific cytotoxic T-cell clone derived from peripheral blood of a melanoma patient after vaccination with gene-modified autologous tumour cells.

Authors:  Y Sun; P Möller; C Berking; E M Schlüpen; M Volkenandt; D Schadendorf
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

4.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

Review 5.  Immune checkpoint inhibitors in melanoma.

Authors:  Adam J Cooper; Matteo S Carlino; Richard F Kefford
Journal:  Melanoma Manag       Date:  2015-08-10

Review 6.  Immune Checkpoint Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure-Response Relationships.

Authors:  Cyril Leven; Maël Padelli; Jean-Luc Carré; Eric Bellissant; Laurent Misery
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

7.  Natural history of cutaneous malignant melanoma.

Authors:  H A Briele; T K Das Gupta
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

8.  Can the clinical course of cancer be influenced by non-antineoplastic drugs?

Authors:  L J Brandes; L A Friesen
Journal:  CMAJ       Date:  1995-09-01       Impact factor: 8.262

9.  Spontaneous regression of metastatic malignant melanoma in 2 sibs with xeroderma pigmentosum.

Authors:  H T Lynch; B C Frichot; J Fisher; J L Smith; J F Lynch
Journal:  J Med Genet       Date:  1978-10       Impact factor: 6.318

10.  Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion.

Authors:  L Ferradini; A Mackensen; C Genevée; J Bosq; P Duvillard; M F Avril; T Hercend
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.